HCW Biologics Inc. (NASDAQ:HCWB) Stock Short Interest Jumps 557.1%

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 60,941 shares, a growth of 557.1% from the September 15th total of 9,274 shares. Approximately 3.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,348,961 shares, the short-interest ratio is presently 0.0 days.

HCW Biologics Price Performance

NASDAQ:HCWB opened at $1.60 on Friday. HCW Biologics has a one year low of $1.50 and a one year high of $27.57. The company has a market cap of $3.58 million, a PE ratio of -0.06 and a beta of 2.41. The firm has a 50-day moving average of $2.45 and a 200-day moving average of $4.18.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings results on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing the consensus estimate of ($1.98) by ($9.60). The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.14 million. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%.

Analyst Ratings Changes

Several research firms have recently issued reports on HCWB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. Wall Street Zen cut HCW Biologics from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $30.00.

About HCW Biologics

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases.

HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic.